Can we have a title here?
Alveus aims to address these critical issues, delivering meaningful improvements in patient outcomes.
In addition to our lead program, we are advancing an amylin pipeline of highly differentiated small molecules, peptides, and novel formats across multiple indications.
Development pipeline
A differentiated therapeutic portfolio
Alveus's pipeline is focused on next-generation metabolic therapies; the lead asset ALV-100 is currently in Phase 2. The company's preclinical amylin pipeline consists of novel peptides, oral small molecules, and other novel formats targeting improved quality of weight loss.
ALV-100
GIPR antagonism + GLP-1R agonism
ALV-200
Amylin pathway · metabolic set-point
Amylin Small Molecule
Oral amylin mimetic · broad access
Fourth program
Novel metabolic mechanism
Clinical trial
ALV-100 is now enrolling for the Phase 2 long-term maintenance study. Learn more about participation and eligibility.